Literature DB >> 22581331

Characterization of P1 promoter activity of the beta-galactoside alpha2,6-sialyltransferase I gene (siat 1) in cervical and hepatic cancer cell lines.

Lorena Milflores-Flores1, Lourdes Millán-Pérez, Gerardo Santos-López, Julio Reyes-Leyva, Verónica Vallejo-Ruiz.   

Abstract

The level of beta-galactoside alpha2,6-sialyltransferase I (ST6Gal I) mRNA, encoded by the gene siat1, is increased in malignant tissues. Expression is regulated by different promoters - P1, P2 and P3 - generating three mRNA isoforms H, X and YZ. In cervical cancer tissue the mRNA isoform H, which results from P1 promoter activity, is increased. To study the regulation of P1 promoter, different constructs from P1 promoter were evaluated by luciferase assays in cervical and hepatic cell lines. Deletion of a fragment of 1048 bp (-89 to +24 bp) increased 5- and 3-fold the promoter activity in C33A and HepG2 cell lines, respectively. The minimal region with promoter activity was a 37 bp fragment in C33A cells. The activity of this region does not require the presence of an initiator sequence. In HepG2 cells the minimal promoter activity was detected in the 66 bp fragment. Sp1 (-32) mutation increased the promoter activity only in HepG2 cells. HNF1 mutation decreased promoter activity in HepG2 cell line but not in C33A cells. We identified a large region that plays a negative regulation role. The regulation of promoter activity is cell type specific. Our study provides new insights into the complex transcriptional regulation of siat1 gene.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22581331     DOI: 10.1007/s12038-012-9194-6

Source DB:  PubMed          Journal:  J Biosci        ISSN: 0250-5991            Impact factor:   1.826


  28 in total

1.  Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT).

Authors:  S Kyo; M Takakura; T Taira; T Kanaya; H Itoh; M Yutsudo; H Ariga; M Inoue
Journal:  Nucleic Acids Res       Date:  2000-02-01       Impact factor: 16.971

2.  Transcription of the beta-galactoside alpha 2,6-sialyltransferase gene in B lymphocytes is directed by a separate and distinct promoter.

Authors:  N W Lo; J T Lau
Journal:  Glycobiology       Date:  1996-04       Impact factor: 4.313

3.  TFII is required for transcription of the naturally TATA-less but initiator-containing Vbeta promoter.

Authors:  B Manzano-Winkler; C D Novina; A L Roy
Journal:  J Biol Chem       Date:  1996-05-17       Impact factor: 5.157

4.  Protein-DNA interactions in the epsilon-globin gene silencer.

Authors:  B Peters; N Merezhinskaya; J F Diffley; C T Noguchi
Journal:  J Biol Chem       Date:  1993-02-15       Impact factor: 5.157

5.  Characterization of a promoter region supporting transcription of a novel human beta-galactoside alpha-2,6-sialyltransferase transcript in HepG2 cells.

Authors:  D A Aas-Eng; H C Asheim; A Deggerdal; E Smeland; S Funderud
Journal:  Biochim Biophys Acta       Date:  1995-03-14

6.  Regulated expression of alpha 2,6-sialyltransferase by the liver-enriched transcription factors HNF-1, DBP, and LAP.

Authors:  E C Svensson; P B Conley; J C Paulson
Journal:  J Biol Chem       Date:  1992-02-15       Impact factor: 5.157

7.  Enhanced sialyltransferases transcription in cervical intraepithelial neoplasia.

Authors:  Dolores López-Morales; Noé Velázquez-Márquez; Olivia Valenzuela; Gerardo Santos-López; Julio Reyes-Leyva; Verónica Vallejo-Ruiz
Journal:  Invest Clin       Date:  2009-03       Impact factor: 0.683

8.  Chromosome mapping and organization of the human beta-galactoside alpha 2,6-sialyltransferase gene. Differential and cell-type specific usage of upstream exon sequences in B-lymphoblastoid cells.

Authors:  X Wang; A Vertino; R L Eddy; M G Byers; S N Jani-Sait; T B Shows; J T Lau
Journal:  J Biol Chem       Date:  1993-02-25       Impact factor: 5.157

9.  The B cell antigen CD75 is a cell surface sialytransferase.

Authors:  I Stamenkovic; H C Asheim; A Deggerdal; H K Blomhoff; E B Smeland; S Funderud
Journal:  J Exp Med       Date:  1990-08-01       Impact factor: 14.307

Review 10.  The biology of the Ets1 proto-oncogene.

Authors:  Jürgen Dittmer
Journal:  Mol Cancer       Date:  2003-08-20       Impact factor: 27.401

View more
  7 in total

1.  Expression of ST3Gal, ST6Gal, ST6GalNAc and ST8Sia in human hepatic carcinoma cell lines, HepG-2 and SMMC-7721 and normal hepatic cell line, L-02.

Authors:  Yan Zhang; Wenjin Zhao; Yujie Zhao; Qun He
Journal:  Glycoconj J       Date:  2015-01-09       Impact factor: 2.916

2.  Expression of N-Acetylglucosaminyltransferase III Suppresses α2,3-Sialylation, and Its Distinctive Functions in Cell Migration Are Attributed to α2,6-Sialylation Levels.

Authors:  Jishun Lu; Tomoya Isaji; Sanghun Im; Tomohiko Fukuda; Akihiko Kameyama; Jianguo Gu
Journal:  J Biol Chem       Date:  2016-01-22       Impact factor: 5.157

Review 3.  Regulation of ST6GAL1 sialyltransferase expression in cancer cells.

Authors:  Kaitlyn A Dorsett; Michael P Marciel; Jihye Hwang; Katherine E Ankenbauer; Nikita Bhalerao; Susan L Bellis
Journal:  Glycobiology       Date:  2021-06-03       Impact factor: 4.313

4.  Reversal effect of ST6GAL 1 on multidrug resistance in human leukemia by regulating the PI3K/Akt pathway and the expression of P-gp and MRP1.

Authors:  Hongye Ma; Lei Cheng; Keji Hao; Yanping Li; Xiaobo Song; Huimin Zhou; Li Jia
Journal:  PLoS One       Date:  2014-01-16       Impact factor: 3.240

5.  Sox2 promotes expression of the ST6Gal-I glycosyltransferase in ovarian cancer cells.

Authors:  Kaitlyn A Dorsett; Robert B Jones; Katherine E Ankenbauer; Anita B Hjelmeland; Susan L Bellis
Journal:  J Ovarian Res       Date:  2019-10-14       Impact factor: 4.234

Review 6.  ST6Gal1: Oncogenic signaling pathways and targets.

Authors:  Sajina Gc; Susan L Bellis; Anita B Hjelmeland
Journal:  Front Mol Biosci       Date:  2022-08-29

7.  ST6GAL2 Downregulation Inhibits Cell Adhesion and Invasion and is Associated with Improved Patient Survival in Breast Cancer.

Authors:  Junchi Cheng; Rong Wang; Guansheng Zhong; Xi Chen; Yun Cheng; Wei Li; Yunshan Yang
Journal:  Onco Targets Ther       Date:  2020-01-29       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.